European Journal of Clinical Investigation,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 28, 2024
Abstract
Background
The
relationship
between
systemic
lupus
erythematosus
(SLE)
and
low‐grade
metabolic
inflammation
(MI)
with
the
microbiota
is
crucial
for
understanding
pathogenesis
of
these
diseases
developing
effective
therapeutic
interventions.
In
this
context,
it
has
been
observed
that
gut
plays
a
key
role
in
immune
regulation
contributing
to
exacerbation
through
inflammatory
mediators.
This
research
aimed
describe
similarities/differences
anthropometric,
biochemical,
inflammatory,
hepatic
markers
as
well
examine
putative
concerning
two
conditions:
SLE
MI.
Methods
Data
were
obtained
from
cohort
comprising
adults
Faecal
samples
determined
by
16S
technique.
Statistical
analyses
compared
anthropometric
clinical
variables,
LEfSe
MetagenomeSeq
used
metagenomic
data.
An
interaction
analysis
was
fitted
investigate
associations
fatty
liver
index
(FLI)
depending
on
condition.
Results
Participants
MI
showed
worse
values
anthropometry
biochemicals
patients
SLE.
profile
unhealthier,
while
no
relevant
differences
found
most
groups.
revealed
an
overrepresentation
Bifidobacteriaceae
family
group.
interactive
association
Bifidobacterium
abundance
type
disease
identified
FLI
values,
suggesting
effect
modification
Conclusion
study
phenotypical
microbial
similarities
disparities
conditions,
evidenced
markers,
interplay
health
(measured
FLI)
occur
different
manner
disease.
These
results
underscore
importance
personalized
approaches
individual
screening
situations,
considering
unique
profiles.
Journal of Fungi,
Год журнала:
2025,
Номер
11(4), С. 279 - 279
Опубликована: Апрель 2, 2025
The
human
gastrointestinal
tract
harbors
a
vast
array
of
microorganisms,
which
play
essential
roles
in
maintaining
metabolic
balance
and
immune
function.
While
bacteria
dominate
the
gut
microbiome,
fungi
represent
much
smaller,
often
overlooked
fraction.
Despite
their
relatively
low
abundance,
may
significantly
influence
both
health
disease.
Advances
next-generation
sequencing,
metagenomics,
metatranscriptomics,
metaproteomics,
metabolomics,
computational
biology
have
provided
novel
opportunities
to
study
mycobiome,
shedding
light
on
its
composition,
functional
genes,
metabolite
interactions.
Emerging
evidence
links
fungal
dysbiosis
various
diseases,
including
inflammatory
bowel
disease,
colorectal
cancer,
disorders,
neurological
conditions.
mycobiome
also
presents
promising
avenue
for
precision
medicine,
particularly
biomarker
discovery,
disease
diagnostics,
targeted
therapeutics.
Nonetheless,
significant
challenges
remain
effectively
integrating
knowledge
into
clinical
practice.
This
review
examines
microbiota,
highlighting
analytical
methods,
associations
with
potential
role
medicine.
It
discusses
pathways
translation,
diagnosis
treatment,
while
addressing
key
barriers
implementation.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(19), С. 10255 - 10255
Опубликована: Сен. 24, 2024
Hematologic
malignancies
(HMs),
including
leukemia,
lymphoma,
and
multiple
myeloma,
involve
the
uncontrolled
proliferation
of
abnormal
blood
cells,
posing
significant
clinical
challenges
due
to
their
heterogeneity
varied
treatment
responses.
Despite
recent
advancements
in
therapies
that
have
improved
survival
rates,
particularly
chronic
lymphocytic
leukemia
acute
lymphoblastic
treatments
like
chemotherapy
stem
cell
transplantation
often
disrupt
gut
microbiota,
which
can
negatively
impact
outcomes
increase
infection
risks.
This
review
explores
complex,
bidirectional
interactions
between
microbiota
cancer
patients
with
HMs.
Gut
influence
drug
metabolism
through
mechanisms
such
as
production
enzymes
bacterial
β-glucuronidases,
alter
efficacy
toxicity.
Moreover,
microbial
metabolites
short-chain
fatty
acids
modulate
host
immune
response,
enhancing
effectiveness.
However,
therapy
reduces
diversity
beneficial
bacteria,
Bifidobacterium
Faecalibacterium,
while
increasing
pathogenic
bacteria
Enterococcus
Escherichia
coli.
These
findings
highlight
critical
need
preserve
during
treatment.
Future
research
should
focus
on
personalized
microbiome-based
therapies,
probiotics,
prebiotics,
fecal
transplantation,
improve
quality
life
for
hematologic
malignancies.
